Cyclopharm Limited (ASX: CYC) is pleased to provide the following update on its progress towards gaining United States Food and Drug Administration (“USFDA”) approval to begin sales of Technegas™ into the US, preliminary (unaudited) revenue performance for FY20 and other operational matters.
For more information, download the attached PDF.
Download this document
